21st September 2011 -- nanoTherics, a UK-based scientific medical research devices company, is pleased to announce launch of the magnefect-nano II™. This new, compact device offers gene transfection with improved efficiencies and cell viabilities, even with a range of difficult cell types such as neuronal and primary cells. It uses a unique technology applying proprietary magnet configurations and oscillating magnet arrays, which can operate at user-definable variable frequencies, to promote magnetic nanoparticle/DNA uptake into cells to improve non-viral gene transfection, whilst maintaining high cell viability. It is simple to use with low running costs (as low as $0.1 per transfection). The device provides improved transfection efficiency and effectiveness over the best currently available cationic lipid agents at short transfection times (<30 minutes). It allows retransfection as well as adherent state transfection for user flexibility. It has been launched as a more compact system to replace the magnefect-nano, which the Company introduced in 2009, and offers full flexibility with interchangeable 6-well, 24-well and 96-well array formats and variable oscillating frequency capability to enable researchers to optimise protocols specifically for the cell types they are using.
Dr Linda E Cammish, Chief Executive Officer, said, “We are delighted to be adding the magnefect-nano II to our product portfolio to enable our customers to improve transfection efficiencies in their research even with hard to transfect cells such as neuronal and primary cells”. She added, “The system has been designed as a direct result of customer feedback to provide a more compact system reducing the valuable laboratory bench and incubator space needs by users. It continues to offer the benefits that oscillating magnet assisted transfection provides such as the high transfection efficiencies and cell viabilities, short transfection times and low running costs.”
nanoTherics Ltd was formed in August 2007 to exploit a novel gene transfection technology arising from biomedical research conducted at Keele University and the University of Florida. The patented technology uses magnetic nanoparticles and oscillating magnetic fields to facilitate improved delivery of biomolecules, including DNA, into living cells. nanoTherics’s gene transfection studies have shown significant performance enhancement over the best non-viral techniques currently on the market, demonstrating high levels of transfection whilst maintaining viability of transfected cells. These key attributes afford a significant competitive advantage over currently available systems. nanoTherics’s primary business is supply of scientific devices and associated products which offer efficiency improvements to research laboratories in the pharmaceutical and biotechnology industries as well as academia. The medium to long-term opportunity for this approach relates to more effective non-viral gene therapy, an area demanding safer technology to treat genetic diseases and disorders including cancers, Parkinson’s disease, multiple sclerosis and cystic fibrosis.
For more information go to www.nanotherics.com
Contact: Dr Linda E Cammish, MBA; CEO: email: firstname.lastname@example.org; Tel: 07981 112968